Abstract #1: EVP-6124 Elicits Pro-Cognitive Effects in Alzheimer's Patients

These data suggest that EVP-6124 administered to AD subjects on stable cholinesterase inhibitor therapies may have potential benefit and that further study in this patient population is indicated. Larger phase II studies are currently being initiated in both Alzheimer's disease and schizophrenia.